Top 20 Shareholders October 2022
Top_Holders_Report OCT
PharmAust doses first patient with MPL in motor neurone disease trial (External link)
PharmAust doses first patient in Phase 1/2 trial of monepantel treating Motor Neurone Disease (External link)
PharmAust (ASX:PAA) doses first patient in MND trial (External ink)
First Patient Dosed in MND Phase 1-2 Trial
PharmAust says MPL can double the life expectancy of dogs with cancer; US trials to begin (External Link)
Update on PharmAust Canine Cancer Trials
PharmAust’s MPL trials show doubled life expectancy for dogs with cancer (External Link)